Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Parikh SV, Aaronson ST, Mathew SJ, Alva G, DeBattista C, Kanes S, Lasser R, Bullock A, Kotecha M, Jung J, Forrestal F, Jonas J, Vera T, Leclair B, Doherty J. Parikh SV, et al. Neuropsychopharmacology. 2024 Jan;49(2):467-475. doi: 10.1038/s41386-023-01751-9. Epub 2023 Oct 24. Neuropsychopharmacology. 2024. PMID: 37875578 Free PMC article. Clinical Trial.
Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial.
Singh B, Parikh SV, Voort JLV, Pazdernik VK, Achtyes ED, Goes FS, Yocum AK, Nykamp L, Becerra A, Smart L, Greden JF, Bobo WV, Frye MA, Burdick KE, Ryan KA. Singh B, et al. Among authors: parikh sv. Psychiatry Res. 2024 May;335:115829. doi: 10.1016/j.psychres.2024.115829. Epub 2024 Feb 28. Psychiatry Res. 2024. PMID: 38479192 Clinical Trial.
National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder.
Niciu MJ, Meisner RC, Carr BR, Farooqui AA, Feifel D, Kaplin A, Kendrick EJ, Kim PM, Schneck CD, Vande Voort JL, Parikh SV. Niciu MJ, et al. Among authors: parikh sv. J Affect Disord. 2024 Feb 1;346:221-222. doi: 10.1016/j.jad.2023.11.008. Epub 2023 Nov 6. J Affect Disord. 2024. PMID: 37940059 No abstract available.
Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression.
Parikh SV, Vande Voort JL, Yocum AK, Achtyes E, Goes FS, Nykamp L, Singh B, Lopez-Vives D, Sera CE, Maixner D, Tarnal V, Severe J, Bartek S, Tye SJ, Rico J, Stoppel CJ, Becerra A, Smart L, Miller CR, Frye MA, Greden JF, Bobo WV. Parikh SV, et al. J Affect Disord. 2024 Mar 1;348:143-151. doi: 10.1016/j.jad.2023.12.033. Epub 2023 Dec 22. J Affect Disord. 2024. PMID: 38142892
Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study.
Schwartzmann B, Chatterjee R, Vaghei Y, Quilty LC, Allen TA, Arnott SR, Atluri S, Blier P, Dhami P, Foster JA, Frey BN, Kloiber S, Lam RW, Milev R, Müller DJ, Soares CN, Stengel C, Parikh SV, Turecki G, Uher R, Rotzinger S, Kennedy SH, Farzan F. Schwartzmann B, et al. Among authors: parikh sv. Transl Psychiatry. 2024 Oct 12;14(1):432. doi: 10.1038/s41398-024-03110-8. Transl Psychiatry. 2024. PMID: 39396045 Free PMC article.
278 results